GENE ONLINE|News &
Opinion
Blog

Ovarian Cancer
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
2023-12-05
Deceptive Health Advice on TikTok Raises Concerns About Gynecologic Cancer Misinformation
2023-09-20
Deep Into Bankruptcy Proceedings, Clovis Sells Cancer Med Rubraca
2023-04-10
Johnson & Johnson to Pay $8.9 Billion Over 25 Years to Settle Talcum Powder Lawsuits
2023-04-06
J&J’s Market Value Plummets by $17 Billion After Appeals Court Denies Bankruptcy Escape
2023-01-31
ImmunoGen Wins FDA Accelerated Approval For Ovarian Cancer Drug
2022-11-16
EMA Recommends Restriction on Rubraca
2022-07-25
Lynparza Bags Multiple Approvals in Japan
2021-01-05
FMI’s Liquid Biopsy Test Adds 3 Companion Diagnostic Indications for Advanced Ovarian, Breast and Lung Cancers
2020-10-30
Korean Biotech, AbClon Enters Trials with New CAR-T Molecule against Ovarian Cancer
2020-04-23
Lynparza Meets Primary Endpoint in Phase III PROfound Trial
2019-08-16
First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer
2018-12-28
LATEST
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
Rising Bird Flu Cases in Cattle and Humans Drive Global Efforts in Vaccination, Genetic Monitoring, and Surveillance
2024-07-17
EVENT
Scroll to Top